TY - JOUR
AU - DuBois, Steven G
AU - Moreno, Lucas
AU - Anderson, John
AU - Asgharzadeh, Shahab
AU - Bagatell, Ro
AU - Beck-Popovic, Maja
AU - Belle, Jen
AU - Berlanga, Pablo
AU - Bird, Nick J
AU - Chesler, Louis
AU - Durbin, Adam
AU - Eggert, Angelika
AU - Eilers, Martin
AU - Federico, Sara M
AU - Fischer, Matthias
AU - Gatz, Susanne A
AU - George, Rani E
AU - George, Sally
AU - Goldsmith, Kelly C
AU - Gray, Juliet
AU - Heczey, Andras
AU - Irwin, Meredith S
AU - Knox, Leona
AU - Lode, Holger N
AU - Ludwinski, Donna
AU - Macy, Margaret E
AU - Majzner, Robbie G
AU - Maris, John M
AU - Modak, Shakeel
AU - Molenaar, Jan J
AU - Morgenstern, Daniel A
AU - Mossé, Yael P
AU - Owens, Cormac
AU - Reynolds, C Patrick
AU - Rossig, Claudia
AU - Schleiermacher, Gudrun
AU - Scott, Liz
AU - Sondel, Paul M
AU - Speleman, Frank
AU - van Noesel, Max
AU - Westermann, Frank
AU - Wienke, Judith
AU - Wolpaw, Adam J
AU - Park, Julie R
AU - Pearson, Andrew D J
TI - Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum.
JO - Pediatric blood & cancer
VL - 72
IS - 9
SN - 1545-5009
CY - New York, NY
PB - Wiley
M1 - DKFZ-2025-01218
SP - e31831
PY - 2025
N1 - 2025 Sep;72(9):e31831
AB - High-risk neuroblastoma is a poor prognosis cancer of the sympathetic nervous system that accounts for a disproportionate number of childhood cancer deaths. Many viable biological targets have been identified, and the number of potential combinations is even larger. Several products have attained marketing authorization for treatment of patients with neuroblastoma. Patient outcomes remain poor, with approximately 50
KW - ALK (Other)
KW - ATR (Other)
KW - B7‐H3 (Other)
KW - EZH2 (Other)
KW - GD2 (Other)
KW - GPC2 (Other)
KW - MYCN (Other)
KW - clinical trials (Other)
KW - drug development (Other)
KW - neuroblastoma (Other)
KW - relapse (Other)
LB - PUB:(DE-HGF)16
C6 - pmid:40509548
DO - DOI:10.1002/pbc.31831
UR - https://inrepo02.dkfz.de/record/302020
ER -